Tecentriq

(Atezolizumab)

ApprovedMonoclonal antibody

Atezolizumab is used to treat certain types of cancer, including lung cancer, bladder cancer, and breast cancer, by helping the body's immune system recognize and fight cancer cells.[2] Tecentriq is currently approved and in use across 129 indications[4].[1]

Tecentriq is one of 1460 monoclonal antibody programs targeting Melanoma. It is currently in Approved.

129

Indications

685

Total Trials

Active Trials

1,459

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

MelanomaTerminated

Small Cell Lung CancerCompleted

Liver TransplantActive, not recruiting

Cervical CancerActive, not recruiting

Squamous Cell CarcinomaUnknown status

Triple-Negative Breast CancerCompleted

Biliary Tract CancerActive, not recruiting

TreatmentTerminated

RadiotherapyTerminated

Rare TumorCompleted

MelanomaPhase 3

Terminated

Small Cell Lung CancerPhase 3

Completed

Liver TransplantApproved

Active, not recruiting

Cervical CancerPhase 2

Active, not recruiting

Squamous Cell CarcinomaPhase 3

Unknown status

Triple-Negative Breast CancerPhase 3

Completed

Biliary Tract CancerPhase 2

Active, not recruiting

TreatmentPhase 3

Terminated

RadiotherapyPhase 2

Terminated

Rare TumorPhase 2

Completed

Showing 10 of 129 indications

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Approved

34 2

Adenocard

Astellas

Preclinical

2 3

Zolymbus

AbbVie

Preclinical

1 4

Duragesic-100

CCephalon

Preclinical

2 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 6

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 7

Chantix

PPrism Pharmaceuticals

Preclinical

1 8

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 9

Vfend

PPrism Pharmaceuticals

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Pancreatic Cancer

NCT04161755

Phase 2Active, not recruiting

Richter Transformation

NCT04082897

Phase 2Recruiting

Immunotherapy

NCT06771518

Phase 2Recruiting

Non-Squamous NSCLC

NCT04865250

Q1 2027

Phase 2Active, not recruiting

Small Cell Lung Cancer

NCT04334941

Phase 2Active, not recruiting

Breast Cancer

NCT03756298

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer22 trials

A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 2·NCT04426825·23 enrolled

The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy

Completed· Roche logo

Roche··NCT03559647·358 enrolled

Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

Completed· Roche logo

Roche·Phase 3·NCT04471428·366 enrolled

Show 19 more trials

A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 3·NCT03735121·438 enrolled

A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 2·NCT03563716·135 enrolled

A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]

Completed· Roche logo

Roche·Phase 2·NCT01846416·138 enrolled

A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

Completed· Pfizer logo

Pfizer··NCT05834348·5,279 enrolled

A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy

Completed· Roche logo

Roche·Phase 3·NCT02813785·565 enrolled

A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.

Active, not recruiting·NNational Taiwan University Hospital·Phase 2·NCT04147351·22 enrolled

Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer

Unknown status·YYonsei University·Phase 2·NCT05034055·45 enrolled

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Completed· Roche logo

Roche·Phase 3·NCT02409342·572 enrolled

A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy

Completed· Roche logo

Roche·Phase 3·NCT02008227·1,225 enrolled

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

Active, not recruiting·UUniversity of Southern California·Phase 2·NCT05340309·5 enrolled

A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)

Completed· Roche logo

Roche·Phase 3·NCT02657434·578 enrolled

Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer

Completed· Regeneron logo

Regeneron·Phase 1·NCT03438318·29 enrolled

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Completed· Roche logo

Roche·Phase 3·NCT02367781·723 enrolled

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Completed· Roche logo

Roche·Phase 3·NCT02366143·1,202 enrolled

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Recruiting·—·Phase 1/2·NCT04691817·28 enrolled

A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer

Withdrawn· Roche logo

Roche·Phase 2·NCT04611776

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT04989283

A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)

Completed· Roche logo

Roche·Phase 2·NCT02927301·181 enrolled

A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy

Completed· Roche logo

Roche·Phase 3·NCT03191786·453 enrolled

Breast Cancer13 trials

AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer

Terminated·TThe Netherlands Cancer Institute·Phase 2·NCT03147040·23 enrolled

A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT03197935·333 enrolled

A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)

Completed· Roche logo

Roche·Phase 3·NCT03125902·653 enrolled

Show 10 more trials

Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer

Completed·FFondazione Policlinico Universitario Agostino Gemelli IRCCS··NCT05609903·52 enrolled

Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer

Completed·VVanderbilt-Ingram Cancer Center·Phase 2·NCT03206203·106 enrolled

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

Recruiting·GGerman Cancer Research Center·Phase 2·NCT05332561·240 enrolled

Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer

Completed·SSOLTI Breast Cancer Research Group·Phase 1·NCT03802604·28 enrolled

Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients

Recruiting·EEuropean Institute of Oncology·Phase 2·NCT06690840·45 enrolled

A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy

Completed· Roche logo

Roche·Phase 2·NCT02924883·202 enrolled

Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Active, not recruiting·NNational Cancer Center, Korea·Phase 2·NCT03756298·284 enrolled

Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer

Active, not recruiting·SSOLTI Breast Cancer Research Group·Phase 2·NCT04759248·55 enrolled

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

Completed· Roche logo

Roche·Phase 1·NCT02605915·98 enrolled

Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer

Unknown status·PPeter MacCallum Cancer Centre, Australia·Phase 2·NCT04739670·31 enrolled

Hepatocellular Carcinoma11 trials

Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

Recruiting·SSun Yat-sen University··NCT06323382·240 enrolled

Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Terminated·—·Phase 2·NCT04541173·6 enrolled

Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapy

Completed·—··NCT05197504·166 enrolled

Show 8 more trials

Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma

Completed·SSun Yat-sen University··NCT06199297·188 enrolled

A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT06006286

A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista

Completed· Roche logo

Roche·Phase 3·NCT04487067·152 enrolled

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

Suspended·NNorthwestern University·Phase 2·NCT05620771·84 enrolled

Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Unknown status·—··NCT05173298·100 enrolled

Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection

Not yet recruiting·UUniversity of Geneva, Switzerland·Phase 3·NCT07461675·30 enrolled

Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma

Terminated·UUniversity Hospital, Grenoble·Phase 2·NCT05448677·3 enrolled

β-alanine in the Treatment of Advanced Hepatocellular Carcinoma

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT07317414·158 enrolled

Small Cell Lung Cancer7 trials

Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases

Terminated·JJeffrey Clarke·Phase 2·NCT04610684·3 enrolled

A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

Completed· Roche logo

Roche·Phase 3·NCT02763579·503 enrolled

A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 3·NCT04028050·155 enrolled

Show 4 more trials

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

Recruiting· Amgen logo

Amgen·Phase 1·NCT06898957·200 enrolled

Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 2·NCT04622228·56 enrolled

Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer

Recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS··NCT05797493·100 enrolled

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04334941·103 enrolled

Triple-Negative Breast Cancer5 trials

A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer

Completed· Roche logo

Roche·Phase 1·NCT03101280·29 enrolled

Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma

Unknown status·IInfinity Pharmaceuticals, Inc.·Phase 2·NCT03961698·91 enrolled

A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

Completed· Roche logo

Roche·Phase 3·NCT02425891·902 enrolled

Show 2 more trials

A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT04148911·184 enrolled

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Completed· Roche logo

Roche·Phase 1·NCT03800836·139 enrolled

95 more indications

Metastatic Colorectal Cancer5 trials

FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients

Completed·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT03721653·218 enrolled

Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer

Active, not recruiting·UUniversity of Colorado, Denver·Phase 2·NCT06784947·13 enrolled

A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)

Completed· Roche logo

Roche·Phase 2·NCT02291289·1,044 enrolled

Show 2 more trials

FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

Recruiting·GGruppo Oncologico del Nord-Ovest·Phase 3·NCT06733038·238 enrolled

Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

Completed·—·Phase 2·NCT02873195·133 enrolled

Cervical Cancer4 trials

Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer

Active, not recruiting·UUniversitaire Ziekenhuizen KU Leuven·Phase 2·NCT03340376·48 enrolled

Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT03738228·40 enrolled

Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer

Completed·NNykode Therapeutics ASA·Phase 2·NCT04405349·52 enrolled

Show 1 more trial

A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer

Completed· Roche logo

Roche·Phase 2·NCT04300647·172 enrolled

Melanoma4 trials

A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases

Completed· Roche logo

Roche·Phase 2·NCT03625141·80 enrolled

A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma

Completed·LLokon Pharma AB·Phase 1/2·NCT04123470·24 enrolled

Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma

Active, not recruiting·UUnknown Sponsor·Phase 2·NCT04722575·95 enrolled

Show 1 more trial

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Completed· Roche logo

Roche·Phase 3·NCT02908672·514 enrolled

Renal Cell Carcinoma4 trials

A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

Terminated· Roche logo

Roche·Phase 3·NCT04338269·522 enrolled

Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma

Terminated·RRoberto Pili·Phase 1/2·NCT03024437·31 enrolled

A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)

Completed· Roche logo

Roche·Phase 3·NCT02420821·915 enrolled

Show 1 more trial

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma

Completed· Roche logo

Roche·Phase 2·NCT01984242·305 enrolled

Urothelial Carcinoma4 trials

A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection

Terminated· Roche logo

Roche·Phase 3·NCT02450331·809 enrolled

Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma

Completed·SSpanish Oncology Genito-Urinary Group·Phase 2·NCT04602078·82 enrolled

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

Active, not recruiting· Roche logo

Roche·Phase 1·NCT05867121·102 enrolled

Show 1 more trial

Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

Completed· Roche logo

Roche·Phase 3·NCT02807636·1,213 enrolled

Ovarian Cancer3 trials

Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT02659384·122 enrolled

ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

Completed·AARCAGY/ GINECO GROUP·Phase 3·NCT02891824·614 enrolled

A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer

Terminated· Roche logo

Roche·Phase 1·NCT03292172·36 enrolled

Advanced Solid Tumors3 trials

Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT03977467·46 enrolled

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

Completed· Roche logo

Roche·Phase 2·NCT04632992·252 enrolled

Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors

Completed·AAdlai Nortye Biopharma Co., Ltd.·Phase 1·NCT04975958·47 enrolled

Prostate Cancer3 trials

Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

Completed· Roche logo

Roche·Phase 1·NCT02814669·45 enrolled

Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

Completed·UUniversity of Hawaii·Phase 1·NCT03024216·37 enrolled

Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

Withdrawn·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT04272645

Bevacizumab3 trials

First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC

Completed·MMedSIR·Phase 2·NCT04408118·100 enrolled

Atezolizumab Plus Bevacizumab in First Line NSCLC Patients

Completed·FFundación GECP·Phase 2·NCT03836066·41 enrolled

Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC

Completed·—··NCT04862949·131 enrolled

Efficacy and Safety3 trials

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Active, not recruiting· Shanghai Henlius Biotech logo

Shanghai Henlius Biotech·Phase 3·NCT05468489·200 enrolled

A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors

Completed· Roche logo

Roche·Phase 2·NCT03264066·87 enrolled

Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC

Not yet recruiting·FFuzhou General Hospital··NCT07093762·35 enrolled

Immunotherapy3 trials

Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)

Not yet recruiting·—·Phase 3·NCT06719336·182 enrolled

Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab

Recruiting·RRegina Elena Cancer Institute·Phase 2·NCT06771518·37 enrolled

SIRT and Peri-immunotherapy : a New Concept

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris··NCT06971237·60 enrolled

Liver Cancer3 trials

A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev

Active, not recruiting·JJia Fan·Phase 3·NCT04649489·501 enrolled

Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant

Recruiting·UUniversity Health Network, Toronto·Phase 1/2·NCT06725121·48 enrolled

Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)

Recruiting·MMichael Dill·Phase 2·NCT05690048·48 enrolled

Gastric Cancer2 trials

WaKING: Wnt and checKpoint INhibition in Gastric Cancer

Active, not recruiting·RRoyal Marsden NHS Foundation Trust·Phase 1/2·NCT04166721·52 enrolled

Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer

Withdrawn·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT03818997

Acute Myeloid Leukemia2 trials

A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)

Completed· Astellas logo

Astellas·Phase 1/2·NCT03730012·11 enrolled

Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)

Terminated·BBioLineRx, Ltd.·Phase 1/2·NCT03154827·1 enrolled

Soft Tissue Sarcoma2 trials

MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma

Active, not recruiting·CCentre Leon Berard·Phase 1/2·NCT04216953·320 enrolled

SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07049848·50 enrolled

Metastatic Solid Tumors2 trials

A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT02304393·140 enrolled

A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT02350673·70 enrolled

Squamous Cell Carcinoma2 trials

A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

Completed· Roche logo

Roche·Phase 1/2·NCT05459129·12 enrolled

A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

Completed· Roche logo

Roche·Phase 2·NCT04665843·123 enrolled

Pancreatic Cancer2 trials

LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer

Completed·LLokon Pharma AB·Phase 1/2·NCT02705196·51 enrolled

Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04161755·29 enrolled

Locally Advanced or Metastatic Solid Tumors2 trials

Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors

Terminated·NNektar Therapeutics·Phase 1/2·NCT03138889·162 enrolled

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT01375842·661 enrolled

Unresectable2 trials

Atezolizumab+Bevacizumab+SBRT in Unresectable HCC

Recruiting·MMassachusetts General Hospital·Phase 1·NCT05096715·20 enrolled

Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)

Recruiting·TTuen Mun Hospital·Phase 2/3·NCT07293468·106 enrolled

Microsatellite Instability2 trials

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

Recruiting·CCancer Research UK·Phase 2/3·NCT05770102·30 enrolled

A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)

Withdrawn· Roche logo

Roche·Phase 2·NCT06331598

Metastatic Tumors2 trials

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Completed· Roche logo

Roche·Phase 1·NCT03289962·272 enrolled

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

Completed· Roche logo

Roche·Phase 1·NCT02794571·518 enrolled

Rare Tumor2 trials

PLATFORM Study of Precision Medicine for Rare Tumors

Recruiting·—·Phase 2·NCT04423185·770 enrolled

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03108131·49 enrolled

Systemic Therapy2 trials

A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy

Not yet recruiting·TTempest Therapeutics·Phase 3·NCT06680258·740 enrolled

LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC

Terminated·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT05537402·1 enrolled

Chemotherapy2 trials

Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab

Recruiting·SSun Yat-sen University·Phase 2·NCT07192185·30 enrolled

A Study on the Efficacy of Atezolizumab Combined with Chemotherapy

Recruiting·SShanghai Pulmonary Hospital, Shanghai, China··NCT06780826·1,430 enrolled

Bladder Cancer2 trials

Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants

Terminated· Roche logo

Roche·Phase 1/2·NCT02792192·24 enrolled

A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]

Completed· Roche logo

Roche·Phase 3·NCT02302807·931 enrolled

Lymphoma2 trials

Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03120676·3 enrolled

PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)

Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT03357224·26 enrolled

Colorectal Adenocarcinoma2 trials

A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)

Completed· Roche logo

Roche·Phase 3·NCT02788279·363 enrolled

A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma

Terminated· Roche logo

Roche·Phase 1·NCT03866239·47 enrolled

Metastatic Melanoma2 trials

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

Completed·IInxMed (Shanghai) Co., Ltd.·Phase 1·NCT04109456·51 enrolled

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Completed· Roche logo

Roche·Phase 1·NCT01656642·67 enrolled

Total Body Irradiation1 trial

Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation

Recruiting·VVanderbilt-Ingram Cancer Center·Phase 1/2·NCT06110572·18 enrolled

Radiotherapy1 trial

Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC

Terminated·OOncology Institute of Southern Switzerland·Phase 2·NCT04549428·12 enrolled

Colorectal Cancer1 trial

Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

Completed· Amgen logo

Amgen·Phase 1·NCT03256344·36 enrolled

Progressive Disease1 trial

Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib

Terminated·—·Phase 2·NCT04099836·7 enrolled

mCRPC1 trial

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Active, not recruiting·EExelixis·Phase 3·NCT04446117·575 enrolled

Cholangiocarcinoma1 trial

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Terminated·HHalozyme Therapeutics·Phase 1·NCT03267940·85 enrolled

Follicular Lymphoma1 trial

Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03465891·2 enrolled

Mucosal Melanoma1 trial

Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma

Completed· Roche logo

Roche·Phase 2·NCT04091217·43 enrolled

Skin Cancer1 trial

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

Terminated·NNeoImmuneTech·Phase 1/2·NCT03901573·31 enrolled

Lung Cancer1 trial

Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer

Active, not recruiting·NNorwegian University of Science and Technology·Phase 2·NCT03540420·212 enrolled

Locally Advanced1 trial

A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT02650713·228 enrolled

Intestinal Cancer1 trial

A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab

Recruiting·OOncolytics Biotech·Phase 1/2·NCT07280377·122 enrolled

Pilot Study1 trial

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

Terminated·PPeter MacCallum Cancer Centre, Australia·N/A·NCT04801966·3 enrolled

Brachytherapy1 trial

TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT

Recruiting·TThird Affiliated Hospital, Sun Yat-Sen University·N/A·NCT05984511·234 enrolled

Gallbladder Cancer1 trial

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT03201458·86 enrolled

Recurrent or Metastatic1 trial

Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck

Unknown status·CCentre Leon Berard·Phase 2·NCT03818061·33 enrolled

Portal vein thrombosis1 trial

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Recruiting·—·Phase 2·NCT06823375·40 enrolled

Fecal Microbiota Transplantation1 trial

Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab

Recruiting·IIRCCS Azienda Ospedaliero-Universitaria di Bologna·Phase 2·NCT07276100·15 enrolled

Esophageal Cancer1 trial

PDL-1 Targeting in Resectable Oesophageal Cancer

Completed·—·Phase 2·NCT03087864·40 enrolled

Cutaneous Squamous Cell Carcinoma1 trial

Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma

Completed·SStanford University·Phase 2·NCT04710498·20 enrolled

Pediatric Solid Tumor1 trial

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

Recruiting·SSt. Jude Children's Research Hospital·Phase 1/2·NCT05468359·64 enrolled

Endometrial Cancer1 trial

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Recruiting·AAlliance Foundation Trials, LLC.·Phase 1/2·NCT04486352·148 enrolled

Second-line Therapy1 trial

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Recruiting·RReplimune Inc.·Phase 2·NCT05733598·60 enrolled

Advanced1 trial

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT07157969·300 enrolled

Effectiveness1 trial

The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study

Completed·SSun Yat-sen University·N/A·NCT07272265·300 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Completed· Roche logo

Roche·Phase 1/2·NCT03193190·341 enrolled

Measles1 trial

Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab

Terminated·VVyriad, Inc.·Phase 1·NCT02919449·2 enrolled

Advanced Malignancies1 trial

Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies

Terminated· Sanofi logo

Sanofi·Phase 1/2·NCT03637764·107 enrolled

Genitourinary Cancer1 trial

A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT03115801·6 enrolled

Diffuse Large B-Cell Lymphoma1 trial

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Completed· Roche logo

Roche·Phase 1/2·NCT02596971·91 enrolled

Sarcoma1 trial

Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc)

Recruiting·CCentre Antoine Lacassagne·Phase 2·NCT03548428·103 enrolled

Malignant Pleural Mesothelioma1 trial

Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)

Recruiting·GGruppo Oncologico Italiano di Ricerca Clinica·Phase 3·NCT04996017·162 enrolled

Non-squamous NSCLC1 trial

Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC

Recruiting·UUniversity Hospital Heidelberg·Phase 2·NCT04865250·20 enrolled

Richter Transformation1 trial

ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

Active, not recruiting·NNiguarda Hospital·Phase 2·NCT04082897·28 enrolled

Immunogenicity1 trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors

Terminated· Roche logo

Roche·Phase 1/2·NCT02541604·87 enrolled

Tumors1 trial

Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures

Withdrawn·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT06713798

Gastric Adenocarcinoma1 trial

Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)

Unknown status·HHospices Civils de Lyon·Phase 2·NCT04739202·60 enrolled

Radiation Therapy1 trial

Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

Terminated·RRutgers, The State University of New Jersey·Phase 1·NCT04081688·16 enrolled

PD-L1 Antibody1 trial

A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen

Completed· Roche logo

Roche·Phase 3·NCT03016312·759 enrolled

Trial1 trial

The Drug Rediscovery Protocol (DRUP Trial)

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT02925234·1,550 enrolled

Treatment1 trial

Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice

Terminated· Roche logo

Roche·Phase 2/3·NCT05694013·49 enrolled

First-line1 trial

A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC

Not yet recruiting·BBiotheus Inc.·Phase 1/2·NCT06584071·140 enrolled

Metastatic1 trial

Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

Terminated·AAffimed GmbH·Phase 1/2·NCT05109442·112 enrolled

Locally Advanced or Metastatic NSCLC1 trial

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

Active, not recruiting·NNeoImmuneTech·Phase 2·NCT04984811·83 enrolled

Metastatic NSCLC1 trial

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)

Not yet recruiting·JJun Zhang, MD, PhD·Phase 2·NCT05859217·40 enrolled

MPA1 trial

Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy

Terminated·PPalleos Healthcare GmbH·Phase 2·NCT04770272·442 enrolled

Primary Peritoneal Cancer1 trial

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Recruiting·RRonald Buckanovich·Phase 2·NCT05538091·48 enrolled

Advanced Cancers1 trial

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT04471727·232 enrolled

Safety and Efficacy1 trial

A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT02715531·243 enrolled

Carboplatin1 trial

Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin

Withdrawn·QQueen Mary University of London·Phase 1·NCT03498222

Cancer1 trial

A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)

Recruiting·VVall d'Hebron Institute of Oncology·Phase 2·NCT03767075·1,000 enrolled

Immune1 trial

Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC

Completed·WWashington University School of Medicine·Phase 2·NCT03689855·21 enrolled

Macrovascular Invasion1 trial

Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion

Recruiting·—·Phase 2·NCT05992220·138 enrolled

Liver Metastases1 trial

Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab

Completed·—·Phase 2·NCT03698461·20 enrolled

Phase II1 trial

Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT06762808

Tyrosine Kinase Inhibitors1 trial

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

Unknown status·TThe University of Hong Kong·Phase 2·NCT03647956·40 enrolled

Metastatic Cancer1 trial

Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer

No longer available·II-Mab Biopharma US Limited··NCT04869501

Immune Checkpoint Blockade1 trial

Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies

Terminated·—·Phase 1/2·NCT04214418·27 enrolled

NSCLC1 trial

Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

Recruiting·UUniversity of Kansas Medical Center·Phase 1/2·NCT04467723·25 enrolled

Malignant Glioma1 trial

Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma

Withdrawn·DDarell Bigner·Phase 1/2·NCT03973879

Toxicity1 trial

Microbiome Immunotherapy Toxicity and Response Evaluation

Unknown status·CCCTU- Cancer Theme··NCT04107168·1,800 enrolled

Chronic Lymphocytic Leukemia1 trial

A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Completed· Roche logo

Roche·Phase 1/2·NCT02500407·713 enrolled

Combination Therapy1 trial

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

Active, not recruiting·EExelixis·Phase 1·NCT03845166·325 enrolled

Recurrence1 trial

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Recruiting·—·Phase 2·NCT04434040·40 enrolled

Urothelial Cancer1 trial

Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer

Completed·MMatthew Galsky·Phase 1·NCT03359239·10 enrolled

Multiple Myeloma1 trial

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

Completed· Roche logo

Roche·Phase 1·NCT02431208·85 enrolled

Regulatory

FDA Approval Timeline[5]

May 18, 2016

Tecentriq

BLA 761034

May 18, 2016

TECENTRIQ

BLA BLA761034

Sources

References

[1]
ClinicalTrials.gov — 685 trial records for Atezolizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Tecentriq drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Atezolizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Atezolizumab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (BLA 761034). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: PD-L1 Inhibitor[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: Roche